NovoCure Limited Культура компании

Mr. Asaf Danziger has been the Chief Executive Officer and Director of Novocure Limited since 2002 and 2012 respectively. Mr. Danziger joined NovoCure in 2002 with significant experience leading the development of innovative medical technologies in both corporate management and hands-on R&D positions. From 1998 to 2002 he served as the Chief Executive Officer at Cybro Medical Ltd., the Israeli subsidiary of Imagyn Medical Technologies (Irvine, CA). He has particular expertise leading multidisciplinary teams of engineers, scientists and physicians from initial concept design to commercial production. He has been a Director of Novocure Ltd since 2012. He served as a Director at NanoPass Technologies Ltd. He served as a Communications and Electronics Officer in the Israeli Defense Force. Mr. Danziger holds a B.Sc. in Material Engineering from Ben Gurion University of the Negev, Israel, where he specialized in Microelectronics and Biomedicine.

Mr. Kinyip Gabriel Leung, also known as Gabe, served as an Executive Vice President of OSI Pharmaceuticals Inc. since May 21, 2003. Mr. Leung served as the President of Pharmaceutical Business of OSI Pharmaceuticals Inc. since June 2009. His initial responsibilities include developing and implementing OSI Pharmaceuticals Inc.'s commercial strategy, including developing a high-quality unit to support marketing, sales and business development. He initially leads a re-launch of Novantrone(R) for cancer uses in the U.S., and upon the pending closing of OSI Pharmaceuticals Inc.'s acquisition of Cell Pathways, Gelclair(TM). Mr. Leung served as the President of Oncology Business of OSI Pharmaceuticals Inc. since April 2005, where he served as the Chief Business Officer for its oncology and diabetes/obesity therapeutic areas prior to its purchase by Astellas. During his 22-year career in the pharmaceutical and biotech industry, Mr. Leung has extensive experience in commercial product launch, business development, marketing, sales, medical affairs and business operations in global pharmaceutical and biotech organizations. He served as Group Vice President of Global Prescription Business at Pharmacia Corporation and Head, successful Pharmacia Global Oncology franchise. Prior to Pharmacia, Mr. Leung served as marketing executive in Bristol-Myers Squibb's oncology business. He headed OSI Pharmaceuticals Inc.'s Global Oncology Franchise, where his responsibilities included medical affairs, marketing and sales worldwide in over 80 countries. He orchestrated two new product launches and helped build one of the strongest oncology pipelines in the industry through acquisition and in-licensing. From 1991 to 1999 Mr. Leung was at Bristol-Myers Squibb Company (BMS) where he led the growth of Taxol(R) and Paraplatin(R) into the then number one and number two chemotherapeutic agents in the United States and widened the lead for BMS Oncology as the leading oncology franchise. Prior to this, Mr. Leung gained worldwide business development experience at the Eastman Kodak Company and Sterling Drug, Inc. He has been the Chairman of the Global Commercialization Team of NovoCure Limited since October 5, 2011. He served as the Chairman of Delcath Systems, Inc. from September 2013 to September 2014 and its Director from March 2011 to December 11, 2014. He served as a Director of Albany Molecular Research Inc. from November 2010 to February 4, 2016. Mr. Leung served as a Director of NanoMed Pharmaceuticals, Inc., since May 22, 2007. He is a collaborating partner of the National Dialogue on Cancer, a national initiative. Under this initiative, He co-chairs a special task force to design a new Research and Development paradigm to help expedite oncology drug discovery and development. He has been the Vice Chairman of NovoCure Limited since October 5, 2011. He is also vice-chair of the Life Sciences Consortium. He serves as an advisor to the NCI Director. He is an active member of C-Change. He serves as a member of the National Cancer Institute Clinical Trial Advisory Committee (NCI CTAC). Mr. Leung is a pharmacist and trained at the University of Texas at Austin where he earned his B.S. degree with High Honors. He attended graduate school at the University of Wisconsin-Madison where he earned his M.S. degree in Pharmacy, with concentration in pharmaceutical marketing.

Mr. Wilhelmus C. M. Groenhuysen, also known as Wilco, has been the Chief Financial Officer of Novocure Inc. and NovoCure Limited since January 5, 2012. At Novocure, Mr. Groenhuysen has global responsibility for finance, information technology, health policy and strategy. Mr. Groenhuysen served as the Chief Financial Officer and Executive Vice President of Cephalon Inc. since January 28, 2010 and served as its Principal Accounting Officer. He was with Cephalon, Inc. from 2007 to 2011 and was responsible for Worldwide Finance, Commercial Operations & Risk Management. He joined Cephalon in August 2007 as Senior Vice President of Finance. Prior to joining Cephalon he spent 20 years with Philips Electronics in various assignments in Europe, Asia and the United States. He served as Senior Vice President and Chief Financial Officer of Philips Electronics North America Corporation since August 2002. He served as its Senior Vice President and Chief Financial Officer Of Philips Lighting's Lighting Electronics Business Group since September 1997 until August 2002. He also served as Chief Financial Officer of Philips Electronics Thailand Ltd. since September 1994 until September 1997. Before that, he had various responsibilities within The Philips Electronics Group, since joining Philips in the Netherlands in 1987. He has been a Non-Management Director of OptiNose, Inc. since October 2017. He has been a Director of Chemgenex Pharmaceuticals Ltd. since June 2011. He served as a Director of HERE Holding Corporation (alternate name Navteq Corp. ) since September 2003. Mr. Groenhuysen holds a Master's Degree in Business Economics from VU University Amsterdam and graduated as Registered Public Controller at VU University Amsterdam.

Mr. William F. Doyle, also known as Bill, has been Executive Chairman of Novocure Limited since 2009 and also has been its Executive Director since 2004. Mr. Doyle serves as an Advisor of Cutlass Capital, LLC. He has been Managing Partner at WFD Ventures LLC since 2003 and also served as its Managing Director. He has been an Executive Chairman of NovoCure Inc. since May 11, 2016. He serves as an Executive Chairman of Blink Health Ltd. He serves as Executive Director of Inventure, LLC. He was a Member of the Investment team at Pershing Square Capital Management, L.P. from October 2014 to 2016. He served as the Managing Director of Insight Venture Partners LLC, Insight Venture Partners VI, L.P., Insight Venture Partners V, L.P., Insight Venture Partners IV, L.P. He served as Vice President of Johnson & Johnson Innovation - JJDC, Inc. (Johnson & Johnson Development Corporation). He served as a Member of Johnson & Johnson's Medical Devices and Diagnostics Group Operating Committee and was Vice President of Licensing and Acquisitions. He served as Management Consultant at McKinsey & Company, Inc. He was the Founder of Durel Corporation. While at Johnson & Johnson, Mr. Doyle was also Chairman of the Medical Devices Research and Development Council and President of Biosense-Webster, Inc. He has been a Non-Management Director of OptiNose, Inc. since 2010. He serves as a Director of Realink Corporation, CareMessage Inc., Aspire Bariatrics, Inc., Doctors Research Group, Inc., and Prisma Medical Technologies LLC. He served as an Independent Director of Zoetis Inc. from February 03, 2015 to May 17, 2016. He served as a Director of Revitas Inc. from December 1999 to August 24, 2005, Andrew Technologies, LLC until September 15, 2015 and Vision-Sciences Inc. from 2002 to August 12, 2005. He served as a Director of Cadence Network, Inc., Avisena, Inc., BionX Medical Technologies, Inc., NanoPass Technologies Ltd., BioScale, Inc. (alternative name ProterixBio, Inc.), GlobalCare Inc., Novocure Inc., OnStation Corporation, RxCentric.com, Inc., IKANO Communications, Inc. and Cleanwise, Inc. He served as a Non-Executive Director at Advanced Surgical Concepts Limited until April 08, 2016. Mr. Doyle holds an S.B. in Materials Science and Engineering from the Massachusetts Institute of Technology and M.B.A. from Harvard Business School.

Prof. Yoram Palti, M.D., Ph.D., founded Novocure Limited in 2000 and has been its Chief Technology Officer since 2000. Prof. Palti is the Founder of CellSense Ltd. He was the Founder of Carmel Biosensors Ltd. and Novocure Inc. He is a veteran scientist and entrepreneur in the field of bio-physics, bio-sensors and electrophysiology. He serves as a Member of Scientific Advisory Board of Trendlines Incubators Israel Ltd. and Novellusdx Ltd. He has been a Director of Novocure Limited since 2002. He serves as Member of Scientific Advisory Board at Trendlines Medical. He was Head of the Rappaport Institute for Research in the Medical Sciences, the research arm of the Technion Medical School, for 12 years. He was an Associate Professor of Physiology at the University of Maryland School of Medicine. Prof. Palti is a Professor Emeritus of Physiology and Biophysics at the Technion - Israel Institute of Technology, the inventor of TTF therapy. Prof. Palti is the author of more than 40 patents and 70 scientific papers. Prof. Palti received his M.Sc., Ph.D. and M.D. from The Hebrew Univ. Hadassah Medical School and served his residency at The Hebrew Univ. Hadassah Medical School.

Dr. Eilon Kirson,, MD, Ph.D., has been the Chief Science Officer and Head of Research & Development at NovoCure Limited since 2012 and served as its Chief Medical Officer from 2006 to 2012. Dr. Kirson joined Novocure in 2002 and has global responsibility for Novocure's clinical and product development programs, as well as its regulatory strategy. He served as a Vice President of R & D at NovoCure Limited. He leads NovoCure's research and development activities. In this role, he has had responsibility at NovoCure's preclinical research, clinical planning and interactions at the FDA. Before NovoCure, he served as the Head of Electrophysiology at Carmel Biosensensors. Dr. Kirson received his B.Med.Sc., MD and Ph.D. in Physiology-Biophysics from the Hebrew University and underwent his Residency in Neurology at Sheba Medical Center, Tel Ha-Shomer Hospital, Israel.

Mr. Michael Ambrogi, also known as Mike, has been the Chief Operating Officer at NovoCure Limited since 2010 and served its US General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing and service and human resources activities worldwide. Mr. Ambrogi joined Novocure in 2006 and has overall responsibility for Novocure's ongoing clinical, manufacturing and service activities worldwide. He serves as a US General Manager of NovoCure Ltd. Mr. Ambrogi served as a General Manager of Deka Research and Development inventor Dean Kamen's R&D firm. Earlier in his career, from 1988 to 1990, Mr. Ambrogi was a consultant with McKinsey & Company. Mr. Ambrogi holds S.B. in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).